No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years.
The appropriate dose of progestogen during long-cycle hormone replacement is still under debate. We present preliminary two-year results from an open five-year clinical trial of 132 postmenopausal women. All subjects had long-cycle HRT consisting of 70 days 2 mg oestradiol valerate (E(2)V), followed by 14 days 2 mg E(2)V plus 20 mg medroxyprogesterone acetate, and a seven-day hormone-free period. No endometrial samples with hyperplasia or indicative of malignancy were found at 24 months.
Erkkola
Risto
R
University Central Hospital, Turku, Finland.
Kumento
Ulpu
U
Lehmuskoski
Sirpa
S
Mattila
Leena
L
Mustonen
Mika
M